Comparative Pharmacology
Head-to-head clinical analysis: CIBINQO versus XELJANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIBINQO versus XELJANZ.
CIBINQO vs XELJANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIBINQO (abrocitinib) is a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1, which modulates cytokine signaling involved in inflammatory pathways, including interleukin (IL)-4, IL-13, IL-31, and interferon-gamma, reducing the inflammatory response in atopic dermatitis.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
100 mg orally once daily, with or without food.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy subjects, supporting twice-daily dosing. No significant accumulation after multiple doses.
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Primarily excreted via feces (69%) and urine (20%) after oral administration. Renal elimination accounts for <1% of unchanged drug. Biliary excretion is the major route for metabolites.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Category C
Category C
JAK Inhibitor
JAK Inhibitor